Decuyper II, Pascal M, Van Gasse AL, et al. - As shown in recent research, nsLTP sensitization can present different clinical phenotypes, and the presence of specific IgE antibodies (sIgE) to nsLTPs pose a challenge for predicting clinical outcome, therefore, researchers examined nsLTP-sensitized patients from Antwerp (ANT, Belgium) and Barcelona (BCN, Spain) in order to compare both clinical and in vitro allergy characteristics as well as a basophil activation test (BAT) and sIgG4 in terms of diagnostic performance in these patients. They found that clinically relevant Mal d 3 sensitization could be detected only by ratios of sIgG4/sIgE rMal d 3 and BAT rMal d 3 (0.001 µg/mL) in BCN, with a sensitivity of 60%-63% and a specificity of 75%-67%, respectively. Added value was demonstrated only by the sIgE/total IgE rPru p 3 ratio (sensitivity 60% and specificity 83%) in ANT. Across regions, a significant difference was seen in nsLTP-associated allergy profiles and diagnostic performance, which were also shown to be component-specific, and this makes extrapolation of data difficult to do. Possible geographical differences in basophil sensitivity were suggested.